Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 15, Number 8—August 2009


Increase in Pneumococcus Macrolide Resistance, United States

Stephen G. JenkinsComments to Author  and David J. Farrell
Author affiliations: Weill Cornell Medical College, New York, NY, USA (S.G. Jenkins); Quotient Bioresearch Ltd, London, UK (D.J. Farrell)

Main Article

Table 1

Erythromycin resistance among Streptococcus pneumoniae isolates, year 5 (2004–2005) and year 6 (2005–2006) of the PROTEKT US surveillance study*

   US region†    Isolates, no. resistant/no. submitted (%)
   Year 5    Year 6
   Northeast    518/1,931 (26.8)    662/2,102 (31.5)
   North Central    467/1,314 (35.5)    568/1,395 (40.7)
   Northwest    94/417 (22.5)    108/422 (25.6)
   Southeast    340/998 (34.1)    419/1,064 (39.4)
   South Central    402/1,149 (35.0)    529/1,368 (38.7)
   Southwest    86/448 (19.2)    95/396 (24.0)
   Total    1,907/6,257 (30.5)    2,381/6,747 (35.3)

   *PROTEKT US, Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin, United States.
   †States submitting isolates for testing included Northeast: CT, DE, IN, MA, MD, MI, NJ, NY, OH, PA, RI, VT, and DC; North Central: IA, IL, KS, MN, MD, ND, NE, SD, and WI; Northwest: AK, ID, MT, OR, WA, and WY; Southeast: FL, GA, KY, NC, SC, VA, and WV; South Central: AL, AR, LA, OK, TN, and TX; Southwest: AZ, CA, CO, NM, NV, and UT.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO